U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07843420) titled 'Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus' on Sept. 21.
Brief Summary: The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Chronic Hepatic Pruritus
Cholestatic Liver Disease
Primary Biliary Cholangitis
Cholestasis
Primary Sclerosing Cholangitis
Intervention:
DRUG: Nemolizumab-ilto
Participants will receive nemolizumab-ilto 60 mg subcutaneously at Week 0, followed by 30 mg subcutaneously every 4 weeks during the treatment perio...